Advanced search×

New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia.

Ghayas C Issa, Houry Leblebjian, Aldo M Roccaro, and Irene M Ghobrial

Curr Opin Hematol 18(4):260-5 (2011) PMID 21519243

Waldenstrom macroglobulinemia is a distinct low-grade lymphoproliferative disease. There have been recent significant advances in understanding the underlying pathogenesis of this disease, including genetic and epigenetic regulators of tumor progression.

DOI: 10.1097/MOH.0b013e3283474e5b
Version: za2963e q8za6 q8zbb q8zc2 q8zd6 q8ze2 q8zf2 q8zgf

Similar articles you may find interesting…

  1. The three stages of Alzheimer's disease.
    Author(s) unavailable

    Lancet 377(9776):1465 (2011) PMID 21531256

  2. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Paul G PG Richardson, Edie E Weller, ... Kenneth C KC Anderson

    Blood 116(5):679-86 (2010) PMID 20385792 PMCID PMC3324254

    This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m(2) (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1,...
  3. Cross-talk between tumor cells and the microenvironment at the metastatic niche.
    M J MJ Carlini, M S MS De Lorenzo, and L L Puricelli

    Curr Pharm Biotechnol 12(11):1900-8 (2011) PMID 21470134

    This review presents recent information about the cross-talk between the tumor cells and the microenvironment in the target organ of metastasis at the premetastatic and metastatic stage. The development of metastatic foci is driven not only by the tumor cells intrinsic properties, bu...